title: Once daily insulin detemir in cystic fibrosis with insulin deficiency.
abstract: The aim of this study was to determine if once daily insulin detemir reverses decline in weight and lung function in patients with cystic fibrosis (CF). 12 patients with early insulin deficiency and six with CF related diabetes (aged 7.2-18.1 years) were treated for a median of 0.8 years. Changes in weight and lung function following treatment were compared to pretreatment changes. Before treatment, the change in weight SD score (ΔWtSDS), percentage of predicted forced expiratory volume in 1 s (Δ%FEV(1)) and percentage of predicted forced vital capacity (Δ%FVC) declined in the whole study population (-0.45±0.38, -7.9±12.8%, -5.8±14.3%) and in the subgroup with early insulin deficiency (-0.41±0.43, -9.8±9.3%, -6.8±10.3%). Following treatment with insulin ΔWtSDS, Δ%FEV(1) and Δ%FVC significantly improved in the whole study population (+0.18±0.29 SDS, p=0.0001; +3.7±10.6%, p=0.007; +5.2±12.7%, p=0.013) and in patients with early insulin deficiency (+0.22±0.31 SDS, p=0.003; +5.3±11.5%, p=0.004; +5.8±13.4%, p=0.024). Randomised controlled trials are now needed.
authors.affiliation: Department of Endocrinology, Sydney Children’s Hospital, Randwick, New South Wales, Australia. s.hameed@unsw.edu.au
authors.forename: Shihab
authors.initials: S
authors.lastname: Hameed
authors.forename: John R
authors.initials: JR
authors.lastname: Morton
authors.forename: Penny I
authors.initials: PI
authors.lastname: Field
authors.forename: Yvonne
authors.initials: Y
authors.lastname: Belessis
authors.forename: Terence
authors.initials: T
authors.lastname: Yoong
authors.forename: Tamarah
authors.initials: T
authors.lastname: Katz
authors.forename: Helen J
authors.initials: HJ
authors.lastname: Woodhead
authors.forename: Jan L
authors.initials: JL
authors.lastname: Walker
authors.forename: Kristen A
authors.initials: KA
authors.lastname: Neville
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Campbell
authors.forename: Adam
authors.initials: A
authors.lastname: Jaffé
authors.forename: Charles F
authors.initials: CF
authors.lastname: Verge
mesh_terms: D000293:Adolescent; D001786:Blood Glucose / Q000378:metabolism; D015190:Blood Glucose Self-Monitoring / Q000379:methods; D002648:Child; D003550:Cystic Fibrosis / Q000150:complications* / Q000503:physiopathology; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D004334:Drug Administration Schedule; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D007328:Insulin / Q000172:deficiency*; D000069057:Insulin Detemir; D049528:Insulin, Long-Acting / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D011236:Prediabetic State / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D016896:Treatment Outcome; D014797:Vital Capacity / Q000187:drug effects; D015430:Weight Gain / Q000187:drug effects
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D049528:Insulin, Long-Acting; D000069057:Insulin Detemir